West-ward Pharmaceutical
Executive Summary
Generic firm is cleared by FDA on March 30 for ANDA approvals following a two-year effort to bring its manufacturing into compliance with Good Manufacturing Practices. A consent decree entered into by West-ward and FDA in January 1992, which led to a temporary shutdown of production at the company's Eatontown, N.J. plant ('The Pink Sheet" Jan. 20, 1992, T&G-15), has been vacated. West-ward said it has filed two ANDAs and two major supplements with the agency and plans to file four ANDAs for eight dosage strengths by the end of 1994
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth